Enanta Raises $56M in IPO; Soars on First Day Trading
By Jennifer Boggs
Thursday, March 21, 2013
Hepatitis C virus (HCV) player Enanta Pharmaceuticals Inc. priced a $56 million initial public offering (IPO) and received a warm welcome from Wall Street, as its newly listed shares shot up 22.7 percent on its first day of trading.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.